Is Retatrutide legal in the US?
The short answer
Retatrutide is not an FDA-approved drug and is not on the 503A Bulks List as of 2026-08-29. The Pharmacy Compounding Advisory Committee has never considered it, so there is no vote to report — it is investigational, and the routes to it are set out below.
What FDA actually evaluated
FDA assessed Retatrutide for one thing: none by pcac. the phase 3 programme targets obesity, type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis and cardiovascular and kidney outcomes..
Everything a seller advertises it for. No regulator has evaluated retatrutide for any use in a person outside a clinical trial or FDA-authorised expanded access.
Full regulatory status
| FDA-approved drug? | No FDA-approved retatrutide product exists in the United States. It is an investigational drug: Eli Lilly is running it through phase 3 and has not obtained approval for any indication. |
|---|---|
| What has been evaluated | None by PCAC. The phase 3 programme targets obesity, type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis and cardiovascular and kidney outcomes. |
| PCAC recommendation | Never considered — no nomination has reached the committee |
| FDA reviewers' position | Not applicable. Retatrutide has never been nominated for the 503A Bulks List and the Pharmacy Compounding Advisory Committee has never reviewed it, so no FDA reviewer position on compounding it exists. |
| Category 2 status | Not on the 503A Bulks List. Whether retatrutide has ever been formally nominated for FDA's interim categories could not be confirmed from FDA's published summary, which does not list every nominated substance in a readable form. What is established is that the Pharmacy Compounding Advisory Committee has not reviewed it: it was not among the substances considered at the July 2026 meeting, and it is not among those FDA has said it intends to bring to the committee before the end of February 2027. |
| 503A Bulks List today | Not on the 503A Bulks List, and it fails all three routes to lawful 503A compounding: there is no USP or NF monograph for retatrutide, it is not a component of an FDA-approved drug product because no approved product exists, and it does not appear on FDA's 503A bulks list. A compounding pharmacy has no lawful path to it. |
| 503B status | Not on the 503B Bulks List and not in FDA's published interim 503B categories. Outsourcing facilities have no lawful path to it either. |
| Prescription status | There are exactly two lawful ways to receive retatrutide in the US today, and neither involves buying it. Enrol in one of the clinical trials, or have your physician request individual-patient expanded access — Lilly opened a pre-approval expanded access programme (NCT07629401) that was listed as AVAILABLE on 2026-08-06. Expanded access is physician-initiated and requires FDA authorisation and the sponsor's agreement; it is not a purchase, and there is no route in which a website sells it to you legally. |
| Next federal event | No approval decision is scheduled or announced. The cardiovascular and kidney outcomes trial (NCT06383390, 10,000 participants) has a primary completion date of February 2029, and several phase 3 studies read out before then. Any FDA submission and review would follow, so a US approval is not a 2026 event. |
If you compete in sport
No substance-specific WADA determination for retatrutide was located. That means none was found, not that it is permitted — an investigational metabolic agent should be assumed to carry risk for any tested athlete until their anti-doping authority says otherwise in writing.
We could not find a substance-specific ruling. Treat this as unknown, not as permission, and check with your governing body before use.
Why FDA's own reviewers recommended against it
What you can actually do today
Retatrutide is sold widely online as a “research chemical”, labelled “research use only” and “not for human consumption”, at a scale that has drawn FDA enforcement. That phrase is a seller's disclaimer, not an FDA category and not authorisation to inject anything into a person. FDA wrote to Gram Peptides on 31 March 2026 treating products including retatrutide and tirzepatide as unapproved new drugs under section 505(a) and telling the seller that introducing them into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act. Nothing sold that way has been through the identity, purity, potency or sterility checks that apply to a drug, and no clinician is accountable for what is in the vial.
What would have to happen for this to change
- 1FDA completes its own evaluation. The advisory vote is non-binding — FDA can accept or reject it.
- 2FDA publishes a proposed rule in the Federal Register identifying substances proposed for inclusion or exclusion, with its reasoning.
- 3A public comment period opens. Anyone may submit evidence and scientific or legal objections.
- 4FDA reviews the comments and the administrative record.
- 5FDA publishes a final rule, or withdraws or modifies the proposal.
- 6The final rule takes effect and amends the list at 21 CFR 216.23.
Sources
- Drugs@FDA — no approved retatrutide product (openFDA API)
- ClinicalTrials.gov — retatrutide phase 3 programme
- NCT07629401 — pre-approval expanded access, listed AVAILABLE
- NCT06383390 — cardiovascular and kidney outcomes trial
- FDA — bulk drug substances used in compounding under 503A
- FDA 503B Bulks List
- FDA warning letter to Gram Peptides, 31 March 2026
- 21 CFR 216.23
See the status of all seven peptides side by side in the FDA 503A compounding tracker. Or read our full guide to Retatrutide.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.